In summary, re-engineering GDNF as a BBB-penetrating IgG-GDNF fusion protein enables neuroprotection in experimental PD with chronic systemic administration of 1 mg/kg of the fusion protein, and this dose has no effect on tissue histology, serum chemistry, body weight and causes no significant ADA immune response. The gene discussed is GDNF; the disease is Parkinson disease.